Physician profile
Kathryn E Monaghan
NPI 1053156539
$3,026.68
in general payments reported to CMS, 2019-2025
35 companies · $1,859 in 2025
The $1,859 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,168 · 2025: $1,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $292.14 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $264.19 | 2024-2025 | |
| Glaxosmithkline, LLC. | $225.94 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.86 | 2024-2025 | Caplyta |
| Medtronic, INC. | $182.00 | 2024-2025 | Closurefast |
| Exact Sciences Corporation | $159.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Painteq LLC | $157.06 | 2024 | Painteq |
| Astrazeneca Pharmaceuticals Lp | $151.24 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $150.96 | 2024-2025 | |
| Antares Pharma, INC. | $125.17 | 2024-2025 | Xyosted |
| Lilly USA, LLC | $123.25 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Radius Health, INC. | $116.55 | 2025 | |
| Alk-Abello, INC | $109.98 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.10 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $60.56 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $54.44 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $50.92 | 2025 | Capvaxive, Gardasil 9 |
| Globus Medical, INC. | $50.59 | 2025 | Senza |
| Axsome Therapeutics, INC. | $44.56 | 2025 | Auvelity |
| Tolmar, INC. | $38.48 | 2024-2025 | Jatenzo |
| Coloplast Corp | $38.42 | 2024 | |
| Astellas Pharma US INC | $33.41 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $31.50 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.47 | 2024-2025 | Xifaxan |
| Hologic Sales and Service, LLC | $31.34 | 2025 | Aptima |
| Amgen INC. | $28.93 | 2025 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $26.28 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $25.43 | 2025 | Austedo Xr |
| Viiv Healthcare Company | $25.33 | 2025 | Apretude |
| Lundbeck LLC | $25.09 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $21.27 | 2025 | Unithroid |
| Pfizer INC. | $20.81 | 2024 | |
| Corium, LLC | $20.48 | 2024 | Azstarys |
| Daiichi Sankyo INC. | $18.79 | 2025 | Injectafer |
| Currax Pharmaceuticals LLC | $15.28 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Monaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.